Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Research & Development (2020 - 2025)

Treace Medical Concepts' Research & Development history spans 6 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Research & Development fell 12.82% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $20.3 million, down 1.49%, while the annual FY2025 figure was $20.3 million, 1.49% down from the prior year.
  • Research & Development reached $4.5 million in Q4 2025 per TMCI's latest filing, down from $4.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.6 million in Q1 2025 to a low of $1.9 million in Q1 2021.
  • Average Research & Development over 5 years is $4.0 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 146.64% in 2021, then dropped 12.82% in 2025.
  • A 5-year view of Research & Development shows it stood at $3.4 million in 2021, then rose by 11.02% to $3.7 million in 2022, then increased by 10.75% to $4.2 million in 2023, then grew by 25.48% to $5.2 million in 2024, then dropped by 12.82% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Research & Development are $4.5 million (Q4 2025), $4.7 million (Q3 2025), and $5.5 million (Q2 2025).